Phosphatidylglycerol Is a Physiologic Activator of Nuclear Protein Kinase C*

Abstract

A major mechanism by which protein kinase C (PKC) function is regulated is through the selective targeting and activation of individual PKC isotypes at distinct subcellular locations. PKC βII is selectively activated at the nucleus during G2 phase of cell cycle where it is required for entry into mitosis. Selective nuclear activation of PKC βII is conferred by molecular determinants within the carboxyl-terminal catalytic domain of the kinase (Walker, S. D., Murray, N. R., Burns, D. J., and Fields, A. P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9156–9160). We previously described a lipid-like PKC activator in nuclear membranes, termed nuclear membrane activation factor (NMAF), that potently stimulates PKC βII activity through interactions involving this domain (Murray, N. R., Burns, D. J., and Fields, A. P. (1994)J. Biol. Chem. 269, 21385–21390). We have now identified NMAF as phosphatidylglycerol (PG), based on several lines of evidence. First, NMAF cofractionates with PG as a single peak of activity through multiple chromatographic separations and exhibits phospholipase sensitivity identical to that of PG. Second, purified PG, but not other phospholipids, exhibits dose-dependent NMAF activity. Third, defined molecular species of PG exhibit different abilities to stimulate PKC βII activity. 1,2-Dioleoyl-PG possesses significantly higher activity than other PG species, suggesting that both fatty acid side chain composition and the glycerol head group are important determinants for activity. Fourth, in vitro binding studies demonstrate that PG binds to the carboxyl-terminal region of PKC βII, the same region we previously implicated in NMAF-mediated activation of PKC βII. Taken together, our results indicate that specific molecular species of nuclear PG function to physiologically regulate PKC βII activity at the nucleus.

Footnotes

  • * This work was supported in part by National Institutes of Health Grant CA56869 (to A. P. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Leukemia Society of America Scholar. To whom correspondence should be addressed: Sealy Center for Oncology and Hematology, University of Texas Medical Branch, Medical Research Bldg., Rm. 9.104, 301 University Blvd., Galveston, TX 77555-1048. Tel.: 409-747-1940; Fax: 409-747-1938; E-mail: afields{at}marlin.utmb.edu.

  • 1 The abbreviations used are: PKC, protein kinase C; DAG, diacylglycerol; PS, phosphatidylserine; NMAF, nuclear membrane activation factor; PG, phosphatidylglycerol; PI-PLC, phosphatidylinositol-specific phospholipase C; PC, phosphatidylcholine; PLA2, phospholipase A2; GST, glutathioneS-transferase; PE, phosphatidylethanolamine.

  • 2 N. R. Murray and A. P. Fields, unpublished results.

    • Received January 29, 1998.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement